Principal Financial Group Inc. Has $178.01 Million Stake in Pfizer Inc. $PFE

Principal Financial Group Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,339,372 shares of the biopharmaceutical company’s stock after buying an additional 32,564 shares during the quarter. Principal Financial Group Inc. owned about 0.11% of Pfizer worth $178,010,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Horizon Financial Services LLC raised its position in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. YANKCOM Partnership bought a new position in Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. raised its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. CICC Research began coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. Morgan Stanley upped their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.50.

Pfizer Price Performance

Shares of PFE opened at $24.24 on Wednesday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a market cap of $138.17 billion, a PE ratio of 18.51 and a beta of 0.35. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The business has a 50-day simple moving average of $25.28 and a two-hundred day simple moving average of $26.18.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.